//
A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial
Ticagrelor With or Without Aspirin After Complex PCI
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy
Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial